


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**COMPLETION OF SUBJECT ENROLLMENT IN PHASE III CLINICAL TRIAL OF**  
**TQB2102 “HER2 BISPECIFIC ADC” FOR HER2-LOW BREAST CANCER**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that TQB2102 “HER2 bispecific ADC”, a national Category 1 innovative drug independently developed by the Group, is currently undergoing a “Randomised, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-selected Chemotherapy in HER2-Low Recurrent/Metastatic Breast Cancer (TQB2102-III-01)”. The enrollment of all subjects has recently been completed.

TQB2102 is a next-generation HER2 dual-epitope bispecific antibody-drug conjugate (ADC) independently developed by the Group, which achieves an optimized balance between efficacy and safety through three core technological innovations.

1. **Dual-epitope targeting design:** The antibody end employs an asymmetric structural design that simultaneously binds to the ECD II/IV domains of HER2, which significantly enhances selectivity toward tumor cells and drug endocytosis efficiency, thereby boosting anti-tumor activity.
2. **Cleavable linker:** Utilizing an enzyme-cleavable linker, TQB2102 is capable of efficient cleavage to release toxins and possesses a “bystander effect,” eliminating surrounding heterogeneous tumor cells to broaden the killing range.
3. **Optimized drug-to-antibody ratio (DAR):** TQB2102 maintains a stable DAR value of 5.8-6.0 and is conjugated with topoisomerase I (Topo I) inhibitor payloads, thereby enhancing therapeutic efficacy while reducing toxic side effects.

The integration of these core technologies has overcome the limitations of traditional HER2 monoclonal antibodies and single-target ADCs, demonstrating significant potential for TQB2102 in treating HER2-low tumors.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the Group announced the results of Phase Ib clinical study of TQB2102 for HER2-low advanced breast cancer <sup>[1]</sup>, demonstrating favorable efficacy and showing a good safety profile:

Efficacy data: In HER2-low patients who had received multiple prior lines of therapy (median of 4 lines of late-stage systemic therapy and 2 lines of palliative chemotherapy), the overall objective response rate (ORR) was 53.4% (39/73), in which the ORR of the 7.5mg/kg cohort reached 58.3% (21/36). It is worth noting that even among patients who had previously progressed on ADC therapy, 44.4% achieved remission following TQB2102 treatment.

Safety data: Grade  $\geq 3$  treatment-related adverse events (TRAEs) primarily included neutropenia (23.3%), leukopenia (20.6%), anemia (8.2%), and hypokalemia (6.9%). Overall, TQB2102 was well-tolerated.

Breast cancer is the most prevalent malignant tumor among women worldwide. In 2022, China reported approximately 357,000 new cases of breast cancer and approximately 75,000 death cases<sup>[2]</sup>. Among which, approximately 45%-55% of breast cancers are classified as HER2-low expression (i.e. HER2 IHC 1+ or 2+/FISH-). This group of patients forms a heterogeneous population, for whom existing conventional HER2-targeted therapies offer limited clinical benefit, creating an urgent need for novel treatments to improve prognosis<sup>[3-4]</sup>.

In the field of breast cancer, the Group has developed a comprehensive portfolio addressing all major subtypes, including HER2-positive, HER2-low, HR+/HER2-, and triple-negative breast cancer, with coverage spanning the entire treatment spectrum from neoadjuvant, first-line, second-line and later, to adjuvant therapy. This integrated strategy is dedicated to offering new treatment options for a broader patient population.

Sources:

- [1] S Wang, et al. Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study. 2025 ASCO #1090.
- [2] Expert Consensus Writing Group on Tiered Diagnosis and Treatment for Breast Cancer (Single Disease Entity). Expert consensus on tiered diagnosis and treatment of single disease of breast cancer (2025 Edition) [J]. Chinese Journal of Oncology, 2025, 47(10): 961-980.
- [3] Louis Fehrenbacher, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 Feb 10;38(5):444-453.

- [4] Howard A Burris 3rd, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 Feb 1;29(4):398-405.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 10 February 2026

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*